



A Window to the
Israeli Pharma and Biotech Industries
Workshop Agenda

23/2/2020-27/2/2020



מדעניות ומדענים יקרים,

ברוכות וברוכים הבאים לסדנת "חשיפה לתעשייה" ה-3 של ארגון ScienceAbroad. תעשייה ה- Life Sciences בישראל עוברת מהפכה ומרגשת בשנים האחרונות. חברות וסטרטאפים רבים נפתחים ובוחרים לקבוע את מרכז המחקר והפיתוח שלהם בישראל והמשקיע הישראלי מגלה סבלנות וסקרנות לתחום מרגש זה, כפועל ישיר מכך כסף רב מושקע בחברות אלו ומעודד צמיחה ופריחה.

בד בבד התעשייה הזו זקוקה לכח אדם איכותי, מוכשר, ידען וסקרן שייקח ויצעיד את התעשייה הזו קדימה ויסייע לה להתפתח ולהפוך את מדינת ישראל – Startup Nation – ל-lifeScience Nation. אתם חברי ScienceAbroad, המנהיגים והמובילים העתידיים של התעשייה הזו ויכולים להצעיד אותה אל המקום בו היא: מקצוענית, מצטיינת, מובילה ופורצת דרך – בדיוק כמו שאנחנו במדינת ישראל יודעות ויודעים לעשות.

במהלך הימים הקרובים תפגשו עם נציגי חברות מובילות וחדשניות במשק הישראלי, תשמעו על מגמות ההתפתחות של התעשייה הישראלית ותזכו ללמוד, יותר מתמיד, על הדרך הנכונה לעבור אל התעשייה הזו.

אנחנו ב-ScienceAbroad החלטנו לסייע לחברי הארגון שלנו למצוא את מקומם בתעשייה הישראלית ובטוחים שבאמצעות חיבורים נכונים והכשרה נכונה נצליח לייצר הצלחות אמיתיות שיקרבו אתכם אל התעשייה הישראלית ואת התעשייה הישראלית אל המקום בו היא צריכה להיות, ויודעים שמהפורום הזה שהתכנס פה בישראל יש סיכוי שנשמע על האקזיט הבא.

ברצוננו להודות לכל השותפים שלנו לסדנה זו ובמיוחד לחברת TEVA על התמיכה והעזרה לאורך השנים ולאחל לכל אחת ואחד מכם הצלחה והנאה מרובה בימים הקרובים. נשמע לשמוע אתכם לאורך כל ימי הסדנה ומקווים שהשלב הבא יהיה רכישת כרטיס טיסה בכיוון אחד, הביתה, לישראל וקליטה בתעשייה הישראלית.

שלכם,

נדב דואני
מנכ"ל

ד"ר שמוליק הס
יו"ר הדירקטוריון

מדענים ישראלים יקרים,
ברוכים הבאים הביתה לישראל.

אנו נרגשים לתת חסות זו השנה השלישית לסדנת ה"חשיפה לתעשיית הפארמה והביוטק בישראל"
ולהיות שותפים לתמיכה במדענים ישראלים ובמחקר אקדמאי מוביל בארץ ובחו"ל.

טבע, שהינה חברה גלובלית הפועלת בכ-60 שווקים, רואה חשיבות אסטרטגית בבניית שיתופי פעולה
מדעיים עם מוסדות אקדמאים וחוקרים מובילים בארץ ובחו"ל. מערכת יחסים הדוקה עם האקדמיה עוד
מהשלבים המוקדמים יכולה להוביל לפיתוח תרופות מתקדמות וטכנולוגיות חדשניות לטובת מיליוני
מטופלים ברחבי העולם.

הכישרון, הניסיון אותו אתם מביאים והחשיפה למעבדות המחקר המובילות בעולם, יאפשרו לתעשיית
הביו-פארמה והאקדמיה הישראלית להמשיך להתפתח ולעמוד בחזית המדע.
לחברת טבע יש שני מרכזי מו"פ מהגדולים בארץ, בנתניה ובכפר-סבא, המתמחים בפיתוח תרופות
חדשניות וגנריות – כימיות וביולוגיות כאחד ונשמח לראותכם משתלבים בעתיד.

אנו רוצים להודות לארגון "סיינסאברוד" על היוזמה והשותפות בקיום הסדנה השבוע
ומאחלים לכם סדנה פורייה ומרתקת,

מתי גיל,
מנהל מדיניות ויחסי ממשל, טבע

דר. דנה בר-און,
מנהלת קשרי אקדמיה, R&D, טבע

A Window to the Israeli Pharma and Biotech Industries Workshop Agenda

February 23-27, 2020

**“Introduction to: Drug Development, Medical Device,
Personalized Medicine and Digital Health”**

Location: STARTUP NATION CENTRAL

Sunday – 23/2/2020

8:30-9:00	Registration and refreshments
9:00-09:30	Greetings
09:30-11:30	Introduction of the participants (I-TED)
11:30-11:45	Coffee break
11:45-13:00	Introduction to drug development - Dr Avri Havron, Biotech Entrepreneur & Adviser, Operon Consultants Ltd.
13:00-14:00	Lunch break
14:00-15:00	Introduction to digital health – Adv. Ophir Shahaf - VP Business Development, eHealth Ventures
15:00-15:45	Personalized medicine and digital health - Dr. Daphna Laifenfeld, Chief Scientific Officer at Ibex Medical Analytics
15:45-16:00	Coffee break
16:00-16:45	Start-ups technologies – success/failure parameters - Mr. Zohar Gendler, Managing Partner and CEO, NGT3
16:45-17:00	Coffee break
17:00-21:00	Mindfulness workshop “The Orange Bike” - Prof. Yesha Sivan (including dinner)



Teva day – Introduction to Drug Discovery and Development

Location: Teva Netanya

Monday – 24/2/2020	
9:00-9:15	Refreshments
9:15-9:45	Greetings - Dr. Yael Marantz, VP Nonclinical development, and head of ABIC site in IL, Teva
9:45-11:15	Introduction to drug discovery and preclinical development – Dr. Aric Orbach, DVM, Senior Director, Head of Pharmacology, Teva
11:15-11:30	Coffee break
11:30-12:15	Planning of a clinical trial – Dr. Eran Harary, VP, Therapeutic Area Head of Neurology & Psychiatry, Global R&D, Teva
12:15-13:00	Personalized medicine- lessons learned and challenges ahead- the case of psychiatry in clinical trials – Dr. Eran Harary, VP, Therapeutic Area Head of Neurology & Psychiatry, Global R&D, Teva
13:00-14:00	Lunch break
14:00-14:45	Introduction into the challenging world of Biosimilars– Dr. Nir Shapir, VP Biologics, CMC Biosimilars, Teva
14:45-15:30	To be on the safe side: Toxicology and ADME in drug development– Dr. Hilla Kedar, Senior Director, Head of Nonclinical Safety, Teva
15:30-16:30	IP and patents in the biopharma world – Dr. Revital Duvdevani, COO, Dr.Eyal Bressler & Co.
16:30-16:45	Coffee break
16:45-18:15	Team pitching for the hackathon – Dr. Dana Bar-On, Director, Head of Academic Affairs and Networks, Teva, and Dr. Tal Yoetz, Manager, Academic Affairs and Network, Teva



Startups and companies

Location: The Faculty of Agriculture Food and Environment, Rehovot - Faculty Club

Tuesday- 25/2/2020

8:30-8:50	Gathering
8:50-9:00	The Faculty of Agriculture Food and Environment, Rehovot - Prof. Masha Niv, Vice Dean for Research and Development
9:00-9:30	Ministry of Aliyah and Integration – Granit Ben Ezra, Director of Division A Absorption in Science
9:30-10:10	Cell therapy – The therapy of the future: opportunities and challenges - Nadav Eshkol, Development Manager, Pluristem Therapeutics Inc
10:10-10:40	Mitochondrial Augmentation Therapy: the path from an idea to possible solution to all mitochondrial diseases - Dr. Natalie Yivgi-Ohana, Ph.D., CEO, Minovia Therapeutics
10:40-11:00	Coffee break
11:00-11:30	Cell and gene therapy, an early perspective - Dr. Shmulik Hess, Ph.D., CEO, Enlivex Therapeutics
11:30-12:15	Life after postdoc - Startup or academia? – Prof. Yanai Ofra, Founder and CEO of Biologic Design and Co-Founder of Ukko
12:15-12:40	The road to success is bumpy - Prof. Oded Shoseyov, Plant Molecular Biology and Nano Biotechnology, CollPlant
12:40-13:30	Lunch
13:30-14:15	Veoli Ltd. - Tzur Di-Cori, Founder & CEO, VEOLI Ltd.
14:15-15:00	IP Perspectives in the World of Cannabis - Avraham Hermon, Associate, Israel, US Practice Groups, US Patent Agent, Israel Patent Attorney. JMB Davis Ben-David, Patents, trademarks and designs
15:00-15:15	Coffee break
15:15-15:45	My personal path from the bench to the clinic - Dr Gili Hart, CEO, Mitoconix Bio. LT



Startups and companies

Location: The Faculty of Agriculture Food and Environment, Rehovot - Faculty Club

Tuesday- 25/2/2020

15:45-16:55	From academia to a successful Israeli AI company – the CytoReason story – Dr. Orit Shaked, Head of Commercial Operations at CytoReason
16:20-17:20	Returning scientists panel - Moderator: Dr. Ianai Fishbein, Associate Director, Nonclinical Development, Teva. Panel members: Moshe Ben-David, PhD - R&D Director, Ukko Anna Zemel - Pharmacology Project Leader, Teva Alina Vodonos Zilberg - Data Scientist, Khealth
17:20-17:30	Coffee break
17:30-18:30	HR Panel – Moderator: Lizi London – Partner and Managing Director – Nisha Panel members: Eti Raihenshtein Zanzuri - Regional TA Delivery Lead Israel, Russia & APAC, IL Recruitment – Teva Tali Bonjack – HR Manager – Cytoreason Pini Orbach, Ph.D. – Head of Pharma – Arkin Holdings
18:30-20:30	Short Job Interviews



Visit Tours

Location: Rehovot/Nes Ziona/Be'er Tuvia/Kfar Saba

Wednesday 26/2/2020

8:30 - 10:20	Scivac – Rehovot - Avi Mazaltov – Global Head of Manufacturing and Rehovot Site General Manager
9:00 - 10:25	FutuRx – Nes Ziona
11:15 - 13:00	BTG - Be'er Tuvia
14:00	Lunch in Teva, Kfar Saba
14:30	Teva, Kfar Saba - Drug Development- how does it look like? - Dr. Bianca Avramovitch, Senior Director GxR&D Analytical Technologies, teva. Including a lecture on: Generic R&D by Dr. Daniella Gutman, VP, Generic R&D, and site head Israel & Hungary, Teva.

From Academic Innovation to Inventions – Mini Hackathon organized by Teva and Amazon Healthcare

Location: Amazon Healthcare, Tel Aviv

Thursday – 27/2/2020

8:30-9:00	Registration and teams formation
9:00-19:00	Hacking - Ready, Set, Go
09:00-09:30	Introduction and Hackathon Framework - Dr. Dana Bar-On, Teva and Guy Spigelman, Amazon Healthcare
09:30-17:00	Working in Teams with Mentors Team Workshops How to pitch, presentation tips, patent search, product, business models etc.
17:00	Dry runs with peer review
19:00-21:00	Meetup with Israeli senior industry executives
19:30-20:00	Hackathon presentations and Voting by Jury Members (5 min for each team)
20:00	Announcing the Winners

A Window to Industry Workshop

Speakers - 2020

Dr. Alina Vodonos Zilberg - Data Scientist, K Health



Alina Vodonos Zilberg obtained her PhD in Public Health from Ben-Gurion University where she studied the effect of air pollution exposure on health outcomes. She has also collaborated with physicians at Soroka Medical Center in Israel and Beth Israel Deaconess Medical Center in Boston, performing ongoing clinical and epidemiological studies based on large-scale electronic health records using data science techniques. She continued her research in the field of environmental health as a Postdoctoral Research Fellow at Harvard T.H. Chan School of Public Health. With her return to Israel, Alina joined K Health as a Data Scientist

Dr. Anna Zemel - Pharmacology Project Leader, Teva



Anna works as a Pharmacology Project Leader at Teva, after completing postdoctoral studies in the Cancer Immunology Center at Massachusetts General Hospital, Harvard Medical School. The focus of her project was to determine the role of the immune system in regulation of early stages of breast cancer development. During her postdoc, she gained valuable knowledge in cancer immunology and immunotherapy. Prior to that, she was a doctoral student in the laboratory of Prof. Illana Gozes at Tel Aviv University. As a scientist she's particularly passionate about approaches to interrogate disease associated mechanisms for identification and validation of the new drug targets.

Dr. Aric Orbach, DVM, Senior Director, Head of Pharmacology, Teva



Aric got his bachelor's degree in Biology at the Givat Ram campus of the Hebrew University. He then went on to study veterinary medicine at the Koret School of Veterinary Medicine (Hebrew University). Recently he received an M.B.A from the Peres Academic Center in Rehovot. As a vet, Aric worked on several veterinary projects and served as a practitioner in a small animal clinic in Rishon. Aric joined Teva's R&D in 2001, starting in the non-clinical safety unit, followed by working as a "project leader", overseeing project development from early preclinical studies advancing to clinical stages. Currently, Aric is heading the pharmacology department and working with a team of scientists to provide in-depth insights on drug candidate's activity and potential therapeutic benefits.

Mr. Avi Mazaltov – Global Head of Manufacturing and Rehovot Site General Manager, SciVac Ltd.



Mr. Mazaltov is an operations executive with broad experience across industries in defining, managing, and optimizing manufacturing and supply chain activities. Mr. Mazaltov joined VBI in 2017 from Omrix Biopharmaceuticals (a Johnson & Johnson company). At Omrix, Mr. Mazaltov was responsible for Biosurgery operations in Israel and was a member of the Biosurgery leadership team. Prior to joining Omrix, Mr. Mazaltov led the Operations and Infrastructures division of Alvarion Technologies. Prior to Alvarion, Mr. Mazaltov held various high-ranking operational roles at Teva Pharmaceuticals, including Director, Global Manufacturing and Plant Manager, Kfar Saba, where he managed a production facility with 1,000+ employees. Mr. Mazaltov holds a B.Sc. in Production Management from Ben Gurion University of the Negev, Israel.

Speakers - 2020

Mr. Avraham Hermon - Associate, Israel, US Practice Groups, US Patent Agent, Israel Patent Attorney. JMB Davis Ben-David, Patents, trademarks and designs

Avraham has been certified as a US Patent Agent since 2003 and an Israeli Patent Attorney since 2006. He specializes in pharmaceuticals, biotech, medical devices and medical cannabis. Avraham started his professional career in 2003 at Teva Pharmaceutical Industries Ltd. where he was involved in patent issues relating to Teva's innovative patent portfolio. Since then, he has worked as an IP director for an incubator and for a biotech startup, and has experience in Israeli patent firms. Since 2018, Avraham has been working at the boutique IP firm JMB Davis Ben-David in Jerusalem, where he primarily provides patent assistance to startup companies, hospitals and established companies, assisting them with patent drafting, prosecution and strategy. Avraham holds a degree in chemistry and a degree in intellectual property law.



Dr Avri Havron - Biotech Entrepreneur & Adviser, Operon Consultants Ltd.

Dr. Abraham (Avri) Havron is a 39 year veteran of the biotech industry. Since 2005 and until 2014 when its acquisition by OPKO Health Inc. (NASDAQ: OPK) was completed Avri was Chief Executive Officer and a director of PROLOR Biotech Inc. (NYSE: PBTH). Between 1999 to 2003 Dr. Havron served as V.P. and Chief Technology Officer of Clal Biotechnology Industries Ltd. and prior to that for 12 years as V.P. Manufacturing and Process-Development of BioTechnology General Ltd. (now, a subsidiary of Ferring Pharmaceuticals). Avri was a member of the founding team of Interpharm Laboratories Ltd. (a subsidiary of Merck-Serono) - the first Israeli biotech company, where he served as Director of R&D from 1980 to 1987. During his managerial career Dr. Havron was directly involved in the multi-disciplinary development of many biopharmaceuticals seven of which were approved and are marketed worldwide: Rebif (recombinant beta interferon), Biotropin (recombinant human growth hormone), Bio-Hep-B (3rd generation recombinant hepatitis B vaccine), business".

Biolon and Euflexxa (ophthalmic and orthopedic devices containing bacteria derived hyaluronic acid), bio-similar recombinant Insulin and, Nexxobrid (debridement agent for severe burns). In addition, Phase 3 clinical trial of Somatogron - recombinant long acting human growth hormone developed by Prolor Biotech (later Opko Biologics) was completed successfully in October 2019. Avri has been actively involved in establishing several biotech start-up companies among them Mediwound, Curetech, Prolor-Biotech, Polyheal, PamBio and Enlivex. He is a member of the board of directors of Collplant Biotechnologies Ltd. (NASDAQ: CLGN) and Enlivex Therapeutics Ltd. (NASDAQ: ENLV; TASE: ENLV), was the Chairman of Mediwound during 2001-2003 and later a member of its board from 2014 to 2017 (NASDAQ: MDWD) and from 2010 to 2018 was a member of the board of directors of Kamada Ltd. (NASDAQ: KMDA; TASE: KAMDA). Dr. Havron holds a PhD in chemistry from the Weizmann Institute of Science and did his post-doctorate at Harvard Medical School. Avri teaches for the 5 th consecutive year a course in the Feinberg graduate school of the Weizmann Institute of Science titled "Practical aspects of innovative Pharma and Biotech



Dr. Dana Bar-On - Head of Academic Affairs and Networks, Teva

Previously to her role in Teva, she was the head of the industry-academia cooperation at the Sagol School of Neuroscience in Tel Aviv University, the largest neuroscience school in Israel. Dr. Bar-On was the founder and head of BrainBoost and Minducate, two innovation and entrepreneurship centers aimed at creating and advancing new commercial academic ventures and start-ups in the field of brain disorders. Dr. Bar-On did her post doc in Tel Aviv University in collaboration with Cambridge University focusing on developing early diagnosis for Parkinson's disease. She finished her Ph.D in Neurobiology focusing on super-resolution microscopy, simulations and modeling of synaptic proteins, and her B.Sc and M.Sc in distinction in Biotechnology at Tel Aviv University. Dr. Bar-On served as a scientific consultant at several leading financial and high-tech private firms and as a director at the EU Human Brain Project education and curriculum committee.



Speakers - 2020

Dr. Daniella Gutman - VP, Generic R&D and site head Israel & Hungary, Teva



Education: BSc and MSc in Chemistry Technion Israel, PhD in Chemistry, Weizmann Institute Israel, Post Doctorate in Chemistry, ZFL CIBA-GIEGY Basel, Switzerland

Experience:

28 years of R&D experience in pharmaceutical industries.

Joined TEVA in 2007, leading the Israel generic R&D responsible over development of generic drug products in various delivery forms. In addition, was responsible of the R&D of the international markets, gained experience in the different regulations and different market's needs. Experience in development of API and DP, regulations, management and transformation of organization aligned with organization strategy. Prior to joining Teva work in TARO pharmaceutical from 1992, served in several roles with increasing responsibility in the R&D.

Dr. Daphna Laifenfeld - Chief Scientific Officer, Ibex Medical Analytics



Daphna is Chief Scientific Officer at Ibex Medical Analytics, a digital health company using AI and Big Data to create a new modality in cancer diagnostics and personalized medicine.

In this role, Daphna drives all scientific and regulatory activities of the company. Prior to joining Ibex, Daphna served as Head, Personalized Medicine and Diagnostics at Teva Pharmaceuticals, where she supported the discovery, development, differentiation, and led repurposing of Teva's pipeline drugs, in collaboration with the Israeli healthcare sector and multinational companies. Prior to that, Daphna led biomarker and diagnostic development activities within the pipeline of multiple top-10 pharma and fortune 500 companies. She served in several roles with increasing responsibility at Selventa, a system's biology company focused on personalized medicine, and founded the Israeli branch of the company, as Global Head of Diagnostics. Daphna trained as post-doc at Harvard University, after receiving her PhD in Medical Sciences from the Technion.

Dr. Eran Harary - VP, Therapeutic Area Head of Neurology, & Psychiatry Global R&D, Teva



Eran is a medical doctor and a board certified in psychiatry. Eran has more than 14 years-experience in senior global managerial and leadership roles in international large pharmaceutical companies and smaller biotech companies both in Israel and in the US (including Lundbeck and Pfizer Global Headquarters in New York, USA).

Experienced in world-wide Lifecycle Management of pharmaceuticals from concept through all development stages to post approval. Eran earned his MD degree from the Sackler School of Medicine in Tel Aviv, and later trained and practiced as a psychiatrist at the Chaim Sheba Medical Center, Tel- Hashomer.

Speakers - 2020

Ms. Eti Raihenshtein Zanzuri - Regional TA Delivery Lead Israel, Russia & APAC, IL Recruitment, Teva

Eti Raihenshtein is Teva International Market Talent Acquisition Director. In her role, she is responsible for developing talent acquisition strategy and building staffing capabilities to ensure we have the pipeline of talent needed to meet Teva's current and future goals. Eti holds 21 years of comprehensive experience building and leading world-class innovative teams. During her career Eti had worked as Talent Acquisition leaders in big corporates such as Strauss Group and NCR and with this experience, she brings a broad view and insights on the labor market, future workplace and market demand for talents



Dr Gili Hart - CEO, Mitoconix Bio. LTD

Gili is a biotech executive with extensive experience in the life science industry. She has 15 years expertise in pharmaceutical development, ranging from licensing, tech-transfer from academy, preclinical development through conduct of Phase 3 clinical trials. She has a successful track record in managing and enhancing large organizations, proven experience in public and private financing as well as large pharma partnering worldwide and serve on numerous Boards of Directors. She is a dynamic, innovative, and accomplishment-oriented business builder and leader who is passionate about assembling expert teams, nurturing strategic alliances, developing transformative products, and creating value.



Dr. Hilla Kedar - Senior Director, Head of Nonclinical Safety, Teva

Hilla holds a PhD in Zoology from Tel Aviv University, a MSc in Molecular Neuroscience from the Weizmann Institute of Science and a second MSc in Applied Toxicology from Surrey University in the UK, which she completed during her years at Teva. Hilla is a certified Toxicologist, with over 13 years of experience in toxicology and drug development. Prior to working at Teva Hilla worked in Wisebands, and Israeli start up developing a medical device, and in parallel was a lecturer in the Open University in Israel. Hilla is busy spreading the 'word of toxicology' and in building bridges of collaboration within Teva and with academia.



Ms. Lizi London – Partner and Managing Director, Nisha

Lizi is a Co-founder of two "exit" companies and has a vast academic background (M.Sc., Biotechnology, B.A., Pharmacology, B.Sc., Agriculture), and over 18 years of experience in Executive Search. Prior to Nisha, Lizi served in executive marketing and sales positions in leading organizations in the Israeli health care industry. Lizi is a partner at Nisha and the Executive Director of two business units; In 2000, Lizi established the Biomed business unit which has evolved into Israel's leading recruitment agency in the field of life sciences. In 2007, she founded the Cleantech & Infrastructure business unit. Lizi has an extensive experience in placing senior executives such as CEOs and Technology, Operation, Business and Regulation VPs. She has in depth familiarity with a wide spectrum of tech organizations.



Speakers - 2020

Mr. Mati Gill - Head of Government Affairs, Corporate & International Markets, Teva



Mati is the Head of Government Affairs, Corporate & International Markets at Teva Pharmaceutical Industries.

Mati previously served as Chief Operations Officer (COO) of the Teva Global Legal Group and serves as a member of the Board of Directors of Sanara Ventures.

He is also a licensed Lawyer and served as the Executive Director of the Australian Israel Leadership Forum. Until March 2009, Mati served as Chief of Staff of Israel's Minister of Public Security Mr. Avi Dichter.

Mati is an active social entrepreneur in the Israeli community. He co-founded and leads the "Sanhedrin Forum" for young Israeli professionals. A reserve officer at the rank of Major in the IDF, Mati served as Operational Liaison Officer with United Nations Peacekeeping Forces in Lebanon and the Golan Heights and with the United States Army.

Dr. Moshe Ben-David - R&D Director, Ukko



Moshe Ben-David is the R&D Director at Ukko, an early-stage Israeli-American startup focusing on food allergies and sensitivities. Ukko uses patient data, machine learning and AI to guide the engineering of food proteins that can be incorporated into food products, plants or therapeutics. Moshe established the R&D division of Ukko in Israel, and he is currently managing and leading the R&D team.

Before joining Ukko, Moshe conducted research focusing on protein engineering and structural biology in world-leading research groups. He received his MSc and PhD from the Weizmann Institute and did a postdoctoral fellowship at the University of Toronto. During his postdoctoral studies he served as the Regional Manager of ScienceAbroad in Toronto.

Mr. Nadav Eshkol - Development Manager, Pluristem Therapeutics Inc



Nadav Eshkol is the Development Manager at Pluristem Therapeutics, a clinical-stage biotherapy company using placental cells to develop cell therapies for several indications such as inflammation, ischemia, muscle injuries, hematological disorders and exposure to radiation. Holding a Bachelor's degree in Biotechnology from the Technion – Israel Institute of Technology. Nadav has been working in Pluristem in process engineering and process development areas for more than 7 years, starting as a development engineer. Expertise in cells growth in bioreactors, innovative process development, projects and teams management and technology transfer to production.

Previous to Pluristem, Nadav has worked for 5 year in the semiconductors industry, as a process engineer in Tower-Jazz Semiconductors.

Dr. Natalie Yivgi-Ohana - CEO, Minovia Therapeutics



PhD in Biochemistry for the Hebrew University in Jerusalem and Postdoctoral Fellowship in the Weizmann Institute of Science. After more than 15 years of research in the field of mitochondrial science I founded Minovia Therapeutics as a leading mitochondrial company where we develop cell therapies for orphan mitochondrial diseases. I am leading the company in the past 8 years: research and development, fund raising, manage budget and timelines and establish collaborations, both with academic partners and with the industry. Lives in Haifa, married with 4 girls.

Speakers - 2020

Dr. Nir Shapir, VP Biologics, CMC Biosimilars, Teva

PhD from Hebrew University of Jerusalem; Faculty of Agriculture, Food and Environmental Quality Sciences. Post Doc and Research Assistant Professor at the Biotechnology and Biochemistry departments of the University of Minnesota, working on the isolation of several genes and related enzyme expression, purification and characterization. Group Manager leading a "Discovery and Technology" team at Beckman Coulter, Minnesota, assessing new disease related biomarkers, innovative immunoassay technologies and developing an IVD immunoassay. Moreover, leading a multidisciplinary, multisite strategic project for the development of a Point-of-Care device using newly developed innovative immunoassay technology. SVP and Site Head at Medgenics Medical, leading the development of an ex-vivo gene therapy platform for the treatment of protein deficient diseases, and bringing the technology to successful clinical trials both in Israel and the US. My current position at Teva is "VP Biologics, CMC Biosimilars" leading the early stage development of Biosimilars; from cell-line development and clone selection through manufacturing and purification processes development.



Prof. Oded Shoseyov - Plant Molecular Biology and Nano Biotechnology, CollPlant

A faculty member of the Hebrew University of Jerusalem. Prof. Shoseyov's research is in plant molecular biology protein engineering and nano-biotechnology. His group focus on Bio-Inspired Nanocomposite materials. He has authored or co-authored more than 200 scientific publications and is the inventor or co-inventor of 65 patents. Shoseyov is a TED speaker. His talk was translated to 21 languages with more than 1.5 million views. Shoseyov is also co-owner and winemaker of BRAVDO winery (<http://www.bravdo.co.il/home>) named after his mentor, and partner Prof. Ben Ami Bravdo. Prof. Shoseyov received the Outstanding Scientist Polak Award for 2002, the 1999 and 2010 Kay Award for Innovative and Applied Research, The 2012 Israel Prime Minister Citation for Entrepreneurship and Innovation, The 2018 Presidential Award for his contribution to the Economy and Society of Israel. He is the scientific founder of 14 companies.



Adv. Ophir Shahaf - VP Business Development, eHealth Ventures

Adv. Shahaf was trained as a corporate lawyer in Tel-Aviv University and completed his MBA in finance at the Stern School of Business (NYU), with a major in International Business. 1998 - Upon his return to Israel Ophir was part of the founding team at Clal Biotechnology Industries. This company was the first institutional investor in the Life Sciences in Israel and was taken public on the Tel Aviv Stock Exchange (TASE:CBI) with some highly successful portfolio companies such as (Compugen - TASE:CGEN, CureTech and Mediound NASDAQ:MDWD). 2003 - Ophir worked with Protalix as VP BD while it grew from 15 to 120 employees, raised considerable funds from the Pontifax VC and other investors, and entered into a strategic partnership with Pfizer, before being taken public (NYSE:PLX) 2006 - As part of the founding team and CEO at Hadasit Bio (TASE:HBL), was part of the company's IPO and led the company during 5 subsequent rounds of financing (totaling approx. \$ 25 M),



Speakers - 2020

via Conv. Bonds, PIPE's, rights and secondary offerings. The HBL portfolio companies have raised under his guidance an additional \$ 20 M including 6 strategic partnerships and investments from some of the leading VCs and institutional investors in Israel. The company completed an ADR listing on the OTC and successfully completed 5 clinical trials (up to Ph. IIb) as well as various regulatory approvals within the portfolio. Ophir also served as CEO of Nanovibronix - a Med. Dev. company in the Ultrasound space that was taken public (NASDAQ:NAOV). 2013 - Ophir was part of the founding team of eHealth Ventures, an incubator and VC fund which is one of the leading investors in early stage Digital Health companies in Israel, with a focus on Digital Diagnostics and Therapeutics. As VP for Business Development, Ophir manages the deal flow of the incubator, and is responsible for due-diligence, negotiation and closing of the transactions, as well as building value during the incubation period. The incubator has reviewed over 850 projects and companies in the field of digital health and has invested in 8 promising companies. Ophir serves on the board of many of the portfolio companies, as well as on the board of a TASE public company. A native English speaker with legal, financial and scientific education, and over 20 years of experience working within the life science industry (finance, operations, investments, legal, regulatory, IP, buy/sell side). Based in Tel-Aviv, father of 3, enjoys mountain biking, skiing and cooking.

Dr. Orit Shaked - Head of Commercial Operations, CytoReason



Orit Shaked, PhD - Head of Commercial Operations, CytoReason

Orit serves as the Head of Commercial Operations at CytoReason. Prior to CytoReason, Orit served as the CEO of BioRap, the Technology-Transfer Office of the Rappaport Institute, CTO at Meytav technological incubator and as Director at Teva. Orit held several BD and R&D positions in bio start-ups. She was a Director of several biotech companies as well as of ITTN (the Israeli Technology Transfer organization). Orit holds a PhD in Medical Sciences and an MBA from the Technion.

Dr. Pini Orbach – Head of Pharma, Arkin Holdings



Dr. Pini Orbach joined Arkin Holdings in 2010 as head of its pharma division. He sits on the board of several of Arkin's pharmaceutical companies, including UroGen Pharma and Quiet Therapeutics, with which he shares his extensive hands-on experience in drug development and business.

Dr. Orbach's gained his professional record in US-based companies such as Arisaph Pharmaceuticals and Epix Pharmaceuticals (NASDAQ: EPIX), as well as Israel-based companies such as cCAM BioTherapeutics, a cancer immunotherapy company sold to Merck in 2015 for \$605M. He holds a Ph.D from the department of physiology and functional genomics at the University of Florida, and was a postdoctoral fellow at the Cardiovascular Research Center, Harvard Medical School, Massachusetts General Hospital.

Speakers - 2020

Dr. Revital Duvdevani - COO, Dr.Eyal Bressler & Co.

Dr. Duvdevani has over 20 years of experience in research and development of pharmacological treatments and medical devices for various clinical indications. Dr. Duvdevani holds a Ph.D. in Neurobiology from the Weizmann Institute and conducted post-doctoral research at Rutgers University, in the field of brain trauma. Dr. Duvdevani is an experience research and development manager, leading the R&D of biotechnology start-up companies and has taught pharmacology and physiology at the Department of Biotechnology Engineering, Ben-Gurion University for over 14 years. In addition, Dr Duvdevani has a Master's of Science Management and has extensive experience in scientific education, managing the Weizmann Institute's Science Museum.



Dr. Shmulik Hess - CEO, Enlivex Therapeutics

Dr. Hess received his PhD in Pharmaceutical Science from the Hebrew University, Israel and was a research fellow at Harvard-MIT Health Sciences and Technology (HST). Dr. Hess has gained numerous patents and publications in peer reviewed scientific journals. Prior to joining Enlivex, Dr. Hess served as the CEO of Valin Technologies since inception, overseeing the execution of the company activities and its achievements including the development and technology transfer of several biologics and the in-licensing and acquisition of three early stage innovative projects and the further drug development process. Prior to joining Valin Technologies, Dr. Hess was founder and CEO of ActivePx, a biotech company engaged in the development of oral available peptides for the treatment of pain. Following which he served as associate global operations at Scigen LTD (NASDAQ: VBIV), where he supported the establishment of a state of the art vaccine manufacturing facility for SciBvac® as well as a biologic manufacturing facility in India. Dr. Hess is co-founder and chairman of ScienceAbroad, an NGO dedicated to encouraging and supporting the return of Israeli scientists from abroad. Dr. Hess has experience with drug and clinical development, process development, scale-up of biologics and GMP manufacturing.



Dr. Tal Yoetz - Academic Affairs and Network, Teva

Tal joined Teva at 2016 as a senior researcher at the innovative R&D in the CMC-formulation department. In 2018, Tal joined the Academic affairs and networks team at Teva's global R&D, where she is responsible for scouting, initiating, developing, and supporting research collaborations with the academia and with the bio-ecosystem. Tal holds a PhD in Biotechnology and Physical Electronics from Tel-Aviv University and an MSc and BSc in Biotechnology Engineering from Ben-Gurion University (both Magna cum Laude).



Ms. Tali Bonjack – HR Manager, Cytoreason

Tali is CytoReason's HR Manager. She started her career at Intel, and has over 15 years of experience in varied human resources disciplines, specializing in HR management, management consulting, recruitment, and organizational development. She is an MBA graduate from Tel Aviv University.



Speakers - 2020

Mr. Tzur Di-Cori - Founder & CEO, VEOLI Ltd.



A business-oriented executive with a proven record of excellence. More than 20 years of experience in executive positions at several successful medical device and high tech companies. Strong management, business and financial experience. A talented entrepreneur, with exceptional team building capabilities and leadership skills. Highly motivated, ROI oriented and an expert in building business strategy and strategic business plan including funds raising. Served in senior positions in the following of companies (-partial list): Card Guard Ltd-COO&VP Business Development, EZSurgical Ltd -CEO, Lifewatch Technologies Ltd-President, GMEDICAL - President, Motorika Ltd-CEO, Breathe.me Ltd -CEO, Step Of Mind Ltd -CEO, Veoli Ltd.-CEO.

Dr. Yael Marantz - VP Nonclinical development, and head of ABIC site in IL, Teva



Yael received her bachelor's degree in chemistry, her Master's degree in biochemistry, focusing on signal transduction of the GnRH receptor, and a PhD in biophysics, on proton transfer mechanism in Cytochromes, all from Tel Aviv university.

Yael was a founding scientist in a biotech company called EPIX pharmaceutical - a pharmaceutical company based in Lexington MA and Ramat-Gan IL, developing drugs for CNS and inflammation (GPCR's). Yael was involved in the discovery of all the company pipeline (four of them reached clinical trials) and served as a VP computational drug development, head of the IL site (30 employees) a member in the executive team, as well as a member of joint research committees with GSK, Amgen and the CFTR foundation.

Yael joined Teva 10 years ago as a project champion for four biosimilar.

As part of her role, she developed early clinical plans, set the overall work plan and interacted with many functions in the company including commercial, IP, nonclinical, clinical etc. Later on Yael assumed for a short period the role of a project champion for both Azilect and Copaxone focusing on LCM activities, new clinical trials, NDA preparation for new Azilect formulation (not submitted) and preparation for the approval of the 40mg Copaxone. Soon after the Cephalon integration, Yael assumed the role of head of nonclinical. Through these years this role has evolved and she is now responsible for a global group of 130 people in the fields of Tox, DMPK, pharmacology as well as bioanalytical/immunogenicity and biomarkers assays group, the academic affairs and networks group and supports the specialty, generic and TGO organization in various aspects. Through her years in Teva, Yael participated in many company initiatives such as Spring, STEP and was part of the team working on our company leadership frame work. In the last 7 years she is also the head of Abic site.

Prof. Yanai Ofran - Founder and CEO, co-Founder, Ukko Inc.



Prof. Ofran, a biophysicist, heads the Lab of Systems Biology and Functional Genomics at Bar Ilan University in Israel. He is the co-founder and Chairman of Ukko, a startup combining AI with advanced genome technologies to solve food allergies and sensitivities. Prof. Ofran is also the founder and CEO of Biologic Design, a biopharmaceutical company using AI to design new biological drugs. Prof. Ofran received his PhD in molecular biophysics and biomedical informatics from Columbia University.

Speakers - 2020

Prof. Yesha Sivan - Founder and CEO, i8 ventures

Prof. Yesha Sivan the founder and CEO of i8 ventures (<http://i8.ventures>) – a business platform focusing on “Innovating innovating.” He is also a visiting professor of digital, innovation and venture at the Chinese University of Hong Kong Business School. Sivan’s professional experience includes developing and deploying innovative solutions for corporate, hi-tech, government, and defense environments. He focuses on digital strategy (SVIT – Strategic Value of Innovation Technology), innovation and venture (employment black holes), mindful leadership (orange bike workshop), virtual worlds (3D3C platforms), and knowledge age standards (nine keys). After receiving his doctorate from Harvard University, he has taught executives, EMBA, MBA, engineering and design courses in his areas of expertise. His personal blog is <http://www.DrYesha.com>.



Mr. Zohar Gendler - Managing Partner and CEO, NGT3

Managing Partner & CEO of NGT3 which is an early-stage investor structured as a venture capital fund and a holder the Israeli government franchise to operate technological incubator and invest in life-science technologies.

NGT3 portfolio currently includes a diverse portfolio of 20 companies in the fields of medical devices, biotech and pharma.

Former CEO and director of Beta-O2 Technologies for a period of 8 years (a biomedical company which developed proprietary implantable bio-artificial pancreas), brought the company to one of the world leaders positioning in the area. Served as CEO of the Technion Entrepreneurial Incubator for a period of 11 years. Led the establishment and investment in more than 50 companies, such as Prolor Biotech (sold to Opko, for \$480M), Mazor Robotics (sold to Medtronic, for \$1.6B), ReWalk (NASDAQ: RWLK, www.rewalk.com), Corindus (sold to Siemens Healthcare, for \$1.1B), Regentis (www.regentis.co.il), Medic Vision (<http://www.medicvision.com/usa/home>), and many others.

Gained a wide range of experience in identifying new technologies and in establishing, directing, and creating value for technology-based start-up companies.

Served as a member of the Technion’s Patent Committee. (1998 – 2006).

Earned his M.Sc. in material engineering, a B.Sc. in physics, and a certificate in business management, all from the Technion, Israel Institute of Technology.



Participants - 2020

Dr. Aryeh Taub



Aryeh received his PhD from the Tel-Aviv University studying cerebro-cerebellar interaction and biocompatibility of chronically implanted microelectrodes. During that time, he developed a biocompatible protein-coated electrode for chronic implantation. During his Ph.D. studies, he was also Group Leader at the Physiology Group for the ReNaChip Project. He did his postdoc at the Weizmann Institute studying brain dynamics. Since 2015 Aryeh is a Staff Scientist in the Department of Neurobiology at the Weizmann Institute. Aryeh studies the neural basis of learning and memory and develops novel electrochemical sensors.

Dr. Aya Tzur Gilat



Aya completed her PhD studies at Tel-Aviv University in the lab of Prof. Yossi Shiloh where she continued her Master research in the field of molecular neurobiology, also at TAU in prof. Daniel Michaelson lab. During her studies she gained valuable knowledge in cell biology, with expertise in neurobiology, trying to better understand the neurological cellular phenotype of Alzheimer disease and Ataxia-Telangiectasia. After graduation she joined the biophysics lab of prof. Ariel Kaplan at the Technion, where they researched single molecule biophysics and used ideas and methodologies from the physical science to study fundamental problems in biology. Her current research at the Technion medical school in Rambam hospital is focused on mammalian telomeres biology in health and disease. In particular, she is interested in the epigenetic arena of human telomeres in human stem cells and different cancer cells. Her research takes advantage of a wide diversity of techniques, such as molecular genetics and human cultures, to microscopy, viral manipulations and more. She enjoys combining the experience she has in diverse fields of research and she is passionate about bringing the bench closer to the clinic. In addition to this, together with collaborators around the world, she is facilitating a well-being courses for Johnson & Johnson daughter companies employees, as part of their mission to be a healthy company.

Dr. David Kain



David Kain is a post-doc at Pablo Blinder's lab at the Sagol school of neuroscience in Tel Aviv university. David did his master's degree and PhD at the Tamman Cardiovascular Research Institute, Sheba Medical Center. Coming to the neuroscience research with great knowledge in the cardiovascular field he is now looking at the link between the brain and the heart. David is also a cardiovascular consultant in Weizmann institute and in private biotech companies.

Dr. Elad Elkayam



Elad obtained his PhD from Ben Gurion University in Biochemistry and Structural Biology. Currently, he is a research investigator at Cold Spring Harbor Laboratory and the Howard Hughes Medical Institute in New York where my research focuses on understanding the molecular basis of nucleic acid regulatory processes, RNAi in particular. He is using the tools of structural biology (x-ray crystallography and cryo-EM), biochemistry and biophysics to study the structure of proteins and protein-nucleic acid complexes associated with these processes to elucidate the mechanisms of small RNAs mediated gene silencing. In recent years Elad has also been part of a multi-institutional effort between Cold Spring Harbor laboratory and NorthWell Health system aimed at finding a specific PIM and DYRK kinases inhibitor based on a natural compound discovered at Cold Spring Harbor Laboratory.

Participants - 2020

Dr. Gadiel Saper

Gadiel is a post-doctoral scientist at Columbia University in the city of New York. He works under Prof. Henry Hess' guidance at the Department of Biomedical Engineering researching engineering aspects and applications with bio-molecular motors. Gadiel began his studies at the Hebrew University of Jerusalem, where he completed in two years, with honors, a three year course in biology and chemistry together with the Amirim Honors program. He followed up with a master's degree in physical chemistry, which he graduated summa cum laude. Gadiel completed his PhD at Technion – Israel Institute of Technology where he studied the multidisciplinary field of bio-solar fuels, specializing in biochemistry and bioelectrochemistry. As part of his research he led an international collaboration of scientists from the fields of biology, chemistry and material engineering from Israel and Germany. This work led to two scientific papers published in Nature Communications journal that sparked widespread interest and were circulated in mainstream Israeli media.



Dr. Hemi Rotenberg

Dr. Hemi Rotenberg is a postdoctoral scholar at the university of Chicago, working in Prof. Bozhi Tian's lab. He graduated all his degrees from the Biotechnology Engineering department at Ben-Gurion University. In his MSc, he worked on perfusion bioreactors for tissue engineering applications. For his PhD, co-mentored by Prof. Smadar Cohen and Prof. Yoram Etzion, he developed a non-invasive and leadless heart pacer using injectable magnetic micro-particles. He is currently interested in the field of electroceuticals and the bio-electric interface, specifically free-standing and leadless technologies for electrical bio-modulation. He is currently developing new silicon-based technologies that allow non-genetic optical modulation of cells and tissues with high specificity and resolution.



Dr. Idit Kosti

Idit is currently a Postdoctoral Researcher at the Bakar Institute for Computational Health Science, University of California San Francisco, in the lab of Prof. Marina Sirota. She studies Women related conditions (pregnancy complications and preterm birth) and disease (Endometriosis) using computational methods, modeling and deep learning. The goal of her projects are to improve diagnosis and prediction using inhouse and publicly available multiple omics data and electronic medical records data. She obtained my Ph.D. in Computational Biology at the Technion, in the lab of Prof. Yael Mandel-Gutfreund. During her PhD she studied regulation along the gene expression pathway in human using computational methods.



Dr. Inbal Raz

Dr. Inbal Raz is a graduate of Joyce & Irving Goldman Medical School of Ben-Gurion University of The Negev, Israel. She relocated to the US at the beginning of her career as a medical doctor in Israel. Her professional interests are diverse, with main emphasis on the fields of psychiatry, neurology, Central Nervous System disorders, pharmacology, immunology and cancer prevention. Dr. Raz completed two externships in psychiatry, at Sheppard Pratt Child and Adolescent Services, Towson, MD, and Medstar Georgetown University Hospital, DC, USA. She participated in an internship at PharmaSite Research, Inc. a company that conducts clinical trials and studies related to pharmacologic treatments of psychiatric and other disorders. Last summer Dr. Raz attended the 'molecular cancer prevention' course at NCI cancer prevention fellowship program, NIH. Dr. Inbal Raz is currently providing ABA therapy for children on the autistic spectrum, in the DC metro area, USA, while working to build career in the healthcare industry.



Participants - 2020

Dr. Keren Di-Nur



Dr. Keren Nevo-Dinur is a Research Associate at the Technion, a molecular-biologist studying one-carbon metabolism in human cancer cells. Her prize-winning PhD investigated mRNA localization in bacteria, overturning the main dogma and awarding her Science paper a place among Science Signaling Ten Breakthroughs of 2011. Next, she diversified her research, from transcription-factors and methylation in plant mitochondria at the Hebrew University in Jerusalem to ribosome binding to antibiotics and IRES-like elements in an international collaboration using MST and Cryo-EM while at the University of British Columbia, Canada. She is a natural-born researcher (no artificial components), excited about the next step in her journey to understand the amazing world of biology and apply it to improve people's lives.

Dr. Lital Attia



Lital received her Bachelor's degree in Biology from the Technion- Israel Technology Institute. During her last year of B.Sc studying she joined Prof. Tom Schulteiss's lab in the Faculty of Medicine at the Technion, where he shared with her the passion of research. She had the privilege to do her Master and Doctoral studies under his supervision, investigating 'the regulatory factors that initiate formation and migration of the nephric duct in the developing embryo'. During that time, she was also working as a lecture associate in Histology, Embryology and Developmental biology for undergraduate medical students' courses. In her research, she came to know the fascinating world of Embryology, which has many aspects in evolution, stem cells, regeneration and cancer. First, she explored the cell fate questions and the environment ability to change the cells destiny. Later, she focused on numerous cell signaling pathways (Wnt, Fgf, chemokins and others) and adhesive molecules to investigate the collective cell migration and movement characteristics of the early kidney-fated cells. Furthermore, to deepen the understanding of this migration, she established a novo in vivo system to visualize and image the collective cell migration in the developing live embryo using florescence gene expression and light microscopy.

Dr. Marianna Truman



Dr. Marianna Truman is a Toxicologist at the Cancer Biology and Cannabinoid Research Laboratory (Biology Faculty, Technion – IIT). Marianna also collaborates with the US National Toxicology Program Laboratory (NIH/NIEHS, NC, USA), at which she conducted her postdoctoral studies (2018-2019). Marianna pursued her Ph.D. (direct track) in Biotechnology and Food Engineering (Technion – IIT, 2016), and between 2016 and 2018 she served as a sole researcher during a feasibility study (Technion – IIT) and early stages of a startup company (Matam High-Tech Park, Haifa). She received her B.Sc. (cum laude) from the Faculty of Biotechnology and Food Engineering and B.A (cum laude) from the Faculty of Biology (Technion – IIT). During her military service at the IDF, Marianna served as an Academic Officer at the Israel Naval Medical Institute. Her research interests span from molecular biology and medical research to biotechnology and mechanical engineering.

Dr. Menachem Katz



Menachem earned his B.Sc. in life sciences at the Tel Aviv University in 1998. He worked in the laboratory of Dr. Lily Vardimon studying the roles of β -catenin in control of cell-to-cell interaction and c-Jun expression. After graduation, Menachem joined the Master's program at the Weizmann Institute of Science where he also earned his Ph.D. in biochemistry in 2006. At Weizmann, he worked with Dr. Yosef Yarden at the Department of Biological Regulation. His thesis focused on EGFR-signaling, its role in cell metastasis, and its regulation by ubiquitin-mediated endocytosis. For his postdoctoral training, Menachem joined the laboratory of Dr. Shai Shaham at The Rockefeller University, NY in 2006. At Dr. Shaham's lab, he studies the roles of astroglia in control of *C. elegans* behavior. His study revealed two important behavioral roles for astrocytes - to control the initiation of sleep as well as to prevent the induction of pathological repetitive behavior.

Participants - 2020

Dr. Michael Telias

Dr. Michael Telias is a neurobiologist currently conducting postdoctoral research at the University of California Berkeley. His current research is focused on the physiology of the retina in health and blindness; and in strategies to restore vision in blind mice and rats. Michael is an expert electrophysiologist as well as a molecular and cell biologist, investigating molecular mechanisms of neurodegenerative disease in animal models from ion channels to visually encoded behavior. During his PhD at the Faculty of Medicine, Tel Aviv University, he established the first model for the study of Fragile X Syndrome in human embryonic stem cells derived from diagnosed blastocysts. He also holds B.Sc.Med. (Medical Sciences) and M.Sc. (Medical Neurobiology) degrees from the Faculty of Medicine, Hebrew University of Jerusalem. He was born in Uruguay and made Aliyah in 2000.



Dr. Nir Ben-Chetrit

Nir is a Postdoctoral Associate in Medicine at Weill Cornell Medical Center. His research seeks to uncover immune evasion mechanisms promoted by tumor-associated macrophages during tumor growth and metastasis.

He earned his Ph.D. in cancer biology at the Weizmann Institute of Science, under the supervision of Prof. Yosef Yarden. He continued to his postdoctoral training with Prof. Johanna Joyce at the Memorial Sloan Kettering Cancer Center and with Dan Landau at Weill Cornell Medicine, NY.

His previous work focused on ECM remodeling and cell-intrinsic growth mechanisms that propelled triple-negative breast cancers invasion and metastasis and yielded novel

translational agents for therapeutic interventions. To identify new potential therapeutic targets, he currently focuses on identifying immunosuppressive mechanisms of the innate immune system. He recognized the unmet need to model the complexity of the tumor microenvironment and target education signals of macrophages in a system that allows high throughput interrogation of cell-cell interactions, which are limited in animals.

He engineered a novel and scalable ex-vivo system that captures the cardinal interactions between murine mammary tumor cells, stroma, T cells, and macrophages while providing read-outs suitable for drug-based and genomic screenings. He was able to enhance the translational potential to human disease and apply a phenotypic "tumor-education" CRISPR screen in primary macrophages to uncover druggable gene targets essential for maintaining immunosuppressive traits.



Dr. Ofir Livne

Ofir Livne is an Israeli board-certified psychiatrist performing epidemiological research in substance use disorders, primarily cannabis use. He received his B.Sc.Med and M.D from Sackler School of Medicine, Tel Aviv University. During his adult psychiatry clinical training, Ofir was an affiliate researcher in Prof. Deborah Hasin's Substance Abuse Epidemiology Lab at Columbia's Mailman School of Public Health. His epidemiologic research collaborations with Prof. Hasin as well as with Prof. Shaul Lev-Ran, Director of the Israel Center on Addiction, focus on social determinants and psychiatric comorbidities of substance use disorders, while applying comprehensive analytical models. His studies draw on large-scale NIH cross-sectional and longitudinal surveys, representative of the U.S general population. Ofir's interests further include digital health and technology-based therapeutic interventions for the immediate and long-term treatment of psychiatric disorders, specifically addictions. He is currently a researcher at Mailman School of Public Health and is planned to begin in spring 2020 a postdoctoral fellowship in psychiatric epidemiology at Columbia University alongside a Master of Public Health at Harvard University.



Participants - 2020

Dr. Ofir Regev



Between the years 2011-2014 Ofir did his BSc in biology at Ben Gurion University (BGU). Following that he proceeded to direct course PhD in the lab of Eyal Gur at (BGU) (2015-2020). In the center of his PhD was a bacterial protein degradation system called the Pup-Proteasome system. Ofir studied the mechanism by which proteins are designated for degradation. Specifically, the interaction mechanism between a ligase and its multiple targets. The research combined computational predictions with detailed biochemical analysis.

Dr. Omer Stern



A clinical pharmacology senior scientist at F-star Therapeutics, Cambridge, UK. Current position: biomarkers lead for a phase I immuno-oncology clinical trial. As a member of the clinical study team Omer manages and analyzes clinical data and design a biomarkers plan to support the study goals. Previously he was a project leader in drug discovery, delivering a bispecific antibody drug candidate from early discovery to advanced preclinical stages and coordinating a multidisciplinary project team. Prior to that he held a postdoctoral position at the MRC Laboratory of Molecular Biology (LMB), Cambridge, UK, Dr Harvey McMahon's group. Main project: exploring the endocytosis of antibody-drug conjugates (ADCs), in collaboration with industry partner MedImmune, using cellular, molecular biology and imaging methods. Omer received my PhD in Clinical Immunology and Microbiology, Tel Aviv University, studying membrane elements within the Dengue virus proteins. MSc and BSc in biology, Tel Aviv University.

Dr. Orna Ernst Rabinovich



Dr. Orna Ernst Rabinovich is a postdoctoral visiting fellow in the Signaling Systems Section at the Laboratory of Immune System Biology, the National Institute of Allergy and Infectious Diseases, NIH, USA. She received her Ph.D. in Biochemistry from Tel Aviv University, Israel, in 2014. Her Ph.D. research focused on the cAMP-mediated regulation of the innate immune response during infection. Using high-content imaging and genome-wide screen, her current research aims to identify novel regulators of the non-canonical inflammasome which detects invading Gram-negative bacteria in the host cell cytosol. Her work delineates the mitochondrial and metabolic processes critical for inflammasome activation and uncovered the role of nucleoside diphosphate kinases D as a mitochondrial fitness checkpoint required to support a robust inflammasome response.

Participants - 2020

Dr. Oshra Betzer

Dr. Betzer is a postdoctoral fellow in the Faculty of Engineering at Bar Ilan University, Israel, and the Institute of Functional Nano & Soft Materials (FUNSOM) at Soochow University, China. She has a PhD in Bioengineering, MSc in Neuroscience, BSc in Computer Sciences, and an additional BSc in Speech Therapy and Audiology. She has 10 years of experience in the high-tech industry, working for Checkpoint (Israel) and Vodafone (UK). During her PhD, she developed theranostic nanoparticle-based therapies for imaging and treatment of various brain pathologies. Her current research focuses on targeted nano-systems delivered via cell- or exosome-mediated strategies, for enhanced drug delivery into the brain and for cancer therapy. Dr. Betzer has published more than 20 papers in prominent journals, presented her work in international conferences, and won several prestigious prizes, including an award for outstanding achievements in research and significance to the field from the Israeli Society for Medical and Biological Engineering (ISMBE), and Best Pre-clinical Paper Award at the World Molecular Imaging Congress (WMIC).



Dr. Polina Weitzenfeld

Polina Weitzenfeld is a scientist at the laboratory of Molecular Genetics and Immunology at the Rockefeller University in New-York City.

She holds a Ph.D in cancer biology and immunology and a B.Sc in medical sciences, both from Tel-Aviv University, Israel.

During her graduate studies, she focused on mechanisms that lead to dissemination of breast tumor cells and formation of remote metastasis.

Following graduation, she was head of clinical trials at "Biop Medical", a medical device start-up, developing a device for early detection of cervical cancer.

In her current post-doctoral project, she engineers antibodies to improve cancer immunotherapies.

When she is not in the lab, she volunteers at the non-profit "My Child's Cancer", searching clinical trials and advocating for patients. She is also passionate about science outreach and communications, lecturing about cancer, immunity and immunotherapy to various audiences.



Dr. Rena Levin-Klein

Rena received her Ph.D. from the Hebrew University of Jerusalem in the summer of 2016. Her thesis work was done under the supervision of Prof. Yehudit Bergman, focusing on epigenetic regulation of the immunoglobulin kappa locus during B cell development. In order to understand this complex process, she utilized a variety of different methods, including classical molecular biology, animal models, primary tissue culture, epigenetic assays (bisulfite, ChIP), CRISPR gene editing and high throughput sequencing (RNA-seq, ATAC-seq, RRBS, VJ-seq, 4C-seq), giving me a broad base of expertise in hands on biological techniques. Rena is currently a postdoctoral scientist in the group of Prof. Reuben Harris at the University of Minnesota. Her work there focuses on effects of APOBEC3 family proteins in a range different cancer types. Rena has found that these proteins affect the genomic sequence of the cancer cells by introducing ongoing mutations at cytosine residues, as well as modifying the epigenetic landscape. She has additionally spearheaded the development of new animal models for studying these proteins. Her postdoctoral work was supported by fellowships from the NIH, as well as the Israel National Postdoctoral Award Program for Advancing Women in Science.



Participants - 2020

Dr. Romina Plitman



Romina is currently a Post-doctoral Researcher in the School of Mechanical Engineering at Tel Aviv University (TAU). She earned her BSc and MSc in Mechanical Engineering from Ben Gurion University of the Negev, Israel and her PhD in Physiology, Development and Neuroscience at the University of Cambridge, UK.

She is interested in the application of three-dimensional image analysis and computational modeling to broaden our understanding of medical complications. Specifically, she is curious about the hemodynamics, structural mechanics, transport phenomena and their interaction in normal and pathological scenarios. Her grand vision is to promote imaging analysis and computational models as diagnostic and solution design tools in pregnancy.

Dr. Ronen Schuster



Ronen is a postdoctoral research fellow at the University of Toronto under the supervision of prof. Boris Hinz. His project deals with interactions between fibroblasts and macrophages during fibrosis and tissue repair. In collaboration with Phenomic AI, a biotech startup, Ronen is currently developing an artificial intelligence-powered drug discovery platform to screen for novel anti-fibrotic medicines.

A certified Israeli pharmacist, Ronen completed his Ph.D. during 2018 at the Faculty of Health Sciences, Ben-Gurion University of the Negev under the supervision of prof. Eli Lewis. His Ph.D. research focused on human α 1-antitrypsin, an endogenous serum protein, and its potential capacity to enhance tissue repair.

Dr. Shai Saroussi



Over the course of the last 12 years, Dr. Saroussi's research focused on elucidating the function of mechanisms that enable an efficient translation of solar energy to primary productivity (through photosynthesis), and to develop the technologies to meet the rising global demands for food, resulted by the rapid growth of the human population on the Earth. Dr. Saroussi was trained and mentored by world leader scientists in the field as Prof. Sven Beer (M.Sc. Tel-Aviv University, Israel), Prof. Nathan Nelson (Ph.D. Tel-Aviv University, Israel), and Prof. Arthur Grossman (Postdoctoral Associate; Carnegie Institution for Science, Stanford, California, USA). Over this period Dr. Saroussi published his scientific achievements in leading scientific literature and presented his findings at prominent international conferences while sponsored by prestige' fellowships and grants by as Levi Eshkol and Bard fellowships and by the US Department of Energy. In addition to leading his own research, Dr. Saroussi enjoyed communicating with other scientists through exciting collaborations which were also published in high impact journals. Moreover, Dr. Saroussi looked for opportunities to contribute to the community: In 2017, Dr. Saroussi chaired the Gordon Research Seminar on Photosynthesis, and over the last few years, reviewed several scientific works for leading international journals.

Dr. Shay Yosef Geula



My name is Shay Yosef Geula, a stem cell scientist with a big passion to understand how we can use stem cells as cell therapy tool. With over than a decade of experience in basic research, I am confident in my abilities to understand stem cells biology, focusing on defining the genetics and epigenetics molecular pathways that regulate the induction, self-renewal and differentiation of mammalian pluripotent and hematopoietic stem cell.

I have hands-on experience with various molecular, biochemical and cellular techniques and vast knowledge in troubleshooting experimentation procedures, strategic planning and posing the next question to advance understanding of any relevant questions that lay ahead.

Participants - 2020

Dr. Sigal Trattner

Sigal Trattner has a PhD in Biomedical engineering. She is currently an adjunct associate research scientist at Columbia University, New York, in the Cardiology-Medicine department. In recent years her research involved methodology for developing dosimetry tools for evaluating radiation risk in cardiac CT scanners. She received her PhD in Tel Aviv university, where she developed an image formation model for a microscope that was used for In Vitro Fertilization (IVF) embryos. Her MSc from Tel Aviv University was in image processing and computer vision and she developed an algorithm for automatic identification of bacterial types. Her BSc from Tel Aviv University was in Industrial engineering.

Sigal has a broad background in Biomedical imaging and her academic work has been highly integrated with industry and hospitals. Her main interests and passion are in recruiting technology and developing devices to solve real problems in the medical world and specifically in medical imaging.



Dr. Tamar Getter

Tamar got her PhD in Chemistry from Bar-Ilan University, Israel.

Former she was a Post-doc researcher at University of California Irvine, expertise in medicinal and organic chemistry.

Dr. Getter was the primary driving force to establish the Small Molecule Screening Facility in the UCI Genomics High-Throughput Facility for the Department of Ophthalmology. She is working to maximize opportunities to translate the insights from basic science investigations into clinical therapeutics.

Her interests entail work at the interface of chemistry and biology to identify and optimize new bioactive small molecules as starting points for novel therapeutics. Interested in dissecting the mechanisms by which retinaldehyde induces retinal toxicity and then using this knowledge to develop therapeutics for diseases in which retinal adducts are thought to play pathogenic roles, in particular Stargardt disease and age-related macular degeneration.



Dr. Yael Weiss-Ottolenghi

Dr. Yael Weiss-Ottolenghi is a Research Associate at the laboratory of Prof. Jonathan M. Gershoni at the School of Molecular Cell Biology and Biotechnology, Tel Aviv University. Her research is focused on profiling the human antibody response towards diseases. Yael received her Ph.D. in Immunology from the Tel Aviv University for her research on characterization of the antibody profile of long term non-progressor HIV infected individuals. She obtained her M.Sc. in Biotechnology (magna cum laude) from the Hebrew University, The Faculty of Agriculture Food and Environment, Rehovot. Her research was focused on Herbicide-resistance conferred by expression of the aldolase (38C2) catalytic antibody in Arabidopsis thaliana. Yael received her B.Sc. in Plant Sciences from the Hebrew University, The Faculty of Agriculture Food and Environment, Rehovot. Yael's research interests include molecular biology, biotechnology and applicative research.



Participants - 2020

Dr. Yan Jouroukhin



Dr. Yan Jouroukhin is a faculty at the Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD. Yan investigates brain metabolic abnormalities related to drug addictions and collaborates with Neurobiology of Relapse Laboratory (NIH/NIDA, MD, USA) and Laboratory of Molecular Neurocircuitry and Motivational Disease (University of Maryland, MD, USA). His work focuses on mitochondrial dysfunction within astrocytes as potential targets for addiction treatment and supported by (NIH/NIMH, Neurochemical Actions of Psychotropic Drugs, Pilot Grant Award, 8/09/19 – 5/31/20). Yan established a platform for real-time imaging of gene expression in live animals

during his Postdoctoral research at Department of Radiology and Radiological Science and Kennedy Krieger Institute, F.M. Kirby Center for Functional Brain Imaging (2012-2014, Johns Hopkins University School of Medicine) and discovered a molecular mechanism underlying cannabis vulnerability during postdoctoral study at Department of Psychiatry and Behavioral Sciences (2014-2018, Johns Hopkins University School of Medicine). In addition, Yan serves on the editorial board for the Journal of Molecular Neuroscience as an animal model expert.

Yan pursued his Ph.D. (direct track) in Human Molecular Genetics and Biochemistry (Sackler School of Medicine, Tel Aviv University, 2013), and between 2012 and 2013 he served as a Scientific consultant at Allon Therapeutics (Vancouver, Canada) and Staff Scientist at Bio-Image - MRI research & consulting (Tel Aviv, Israel). He received her B.Sc. from Bar Ilan University (Molecular, Cell and Medical Biology, 2005).

Dr. Yelena Mostinski



Yelena Mostinski is a postdoctoral researcher at Leibniz-Forschungsinstitut für Molekulare Pharmakologie, Berlin, in the group of Dr. M. Nazaré (joined in 2018). She obtained her Ph.D. degree in Medicinal Chemistry from The Hebrew University of Jerusalem in 2018, under the supervision of Prof. Dmitry Tselikhovsky. Her doctoral research was focused on methodology development for the synthesis of biologically important aliphatic heterocycles and discovery of the new chemical transformation. Currently, her main research interests include design, synthesis, and optimization of the small-molecule based inhibitors of SHP2 phosphatase and development of fluorescent chemical probes for the illumination of cannabinoid receptors.

Dr. Yonatan Sher



Throughout his scientific career Yonatan focused his research on microbial interactions with their environment. During his MSc studies, under the supervision of Prof. Jaap Van Rijn at the Faculty of Agriculture he studied aquaculture water recirculating system. During his PhD studies, under the supervision of Prof. Ali Nejdat and Prof. Zeev Ronen at the Ben-Gurion University, Yonatan examined ammonia oxidizing communities and their associated processes causing nitrate leaching in soil systems. Soil ammonia oxidizers play a key role in the nitrogen cycle of terrestrial ecosystems, especially where oxidized nitrogen (e.g. Nitrate) is accumulating and when water drainage occur nitrate will pollute below ground waters.

After his PhD studies he went on a short postdoc period in the lab of Prof. Oded Beja at the Technion. During this time, Yonatan had implemented a liquid handling robotic system for high throughput analyses. During his postdoc in the lab of Prof. Mary Firestone at UC Berkeley he studied microbial processes controlling EPS production in soil, with postdoctoral fellowships from both BARD and USDA research funds. Yonatan has studied the effect of plant roots on microbial EPS (extracellular polysaccharide) production and soil aggregation. Recent advances in sequencing technology and increased availability of microbial sequenced data revolutionized the way we understand microbial interactions. In a second project he led during his postdoc in UC Berkeley, in a collaboration with Prof. Jill Banfield, he hypothesized that through accurate mapping of meta-transcriptomics sequences to meta-genomic assembled genomes (MAG's) it is possible to learn about physiological conditions microorganisms in their environment habitat senses.

// Great minds think ISRAEL //

teva תודתנו לנותנת החסות

תודות למארחי הסדנה



תודה לכל שותפינו



Contact Information:

Vardit Aradi Gad
vardit@scienceabroad.org.il
Cell: 052-3555419

Nadav Douani
nadav@scienceabroad.org.il
Cell: 054-7573121

Dana Bar-On
Dana.Bar-On@teva.co.il
Cell: 052-3495359

www.scienceabroad.org.il